Bullish case
$500 to $540
More likely if Medicare Advantage margins recover toward management targets, 2027 bids absorb utilization pressure, CenterWell integration improves care economics, and investors pay a premium multiple for EPS recovery.
Humana Inc. research snapshot
HUM AI Stock Analysis
HUM AI stock analysis currently reads Humana as a scaled Medicare Advantage and healthcare services company whose stock has rebounded faster than near-term earnings power. The business has durable member relationships, CenterWell assets, data and care-management capabilities, and a large Medicare platform, but 2026 guidance, Star Ratings pressure, medical cost trends, regulatory exposure, and a high current earnings multiple keep the HUM AI stock forecast scenario-based rather than a single-point prediction.
Current price
$394.62
Market cap
$47.38 billion
AI score
62 / 100
Rating
Medicare Advantage leader with a sharp earnings reset and policy-sensitive margin recovery case
Trend status
Technically strong above major moving averages, fundamentally still in recovery proof mode
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Humana is a long-listed U.S. large-cap with SEC filings, company earnings releases, Medicare Advantage disclosures, market data, technical data, and independent financial databases available for cross-checking.
- bias Check
- The main AI research risk is over-weighting Humana history as a quality managed-care compounder while under-weighting the current margin reset. Public data is abundant, but the investment edge depends on whether medical cost, Stars, bid pricing, and CenterWell execution improve faster than the market already expects.
- ai Confidence
- High for reported FY2025 revenue, net income, share count, market cap, cash, debt, 2026 EPS guidance, and moving-average levels. Medium for normalized earnings power because Medicare Advantage utilization, Stars recovery, CMS rules, and 2027 bids remain moving variables.
- investment Certainty
- Medium-low. The descriptive case is well documented, but investment certainty is lower because the current price already discounts a meaningful earnings recovery from depressed 2026 guidance.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Humana runs a large Medicare-focused insurance platform, pharmacy, primary care, and home health services, with individual Medicare Advantage as the main economic engine. | High |
| Moat | The moat comes from scale, provider networks, Stars processes, data, care management, distribution, and CenterWell integration. It is not immune to CMS policy, utilization, or bid-cycle mistakes. | Medium-high |
| Management | President and CEO Jim Rechtin took the CEO role in July 2024 and is steering a margin recovery, customer experience, and Medicare Advantage operating reset. | Medium |
| Financial trend | FY2025 revenue rose to $129.664 billion and net income attributable to Humana was $1.188 billion, while 2026 adjusted EPS guidance was held at at least $9.00 after Q1. | High |
| Valuation | At $394.62, verified math shows about 42.2x TTM EPS, 32.3x FCF per share, 2.6x book value, and roughly 0.35x sales on the inputs used here. | Medium-high |
| Technical trend | HUM trades above the 50-day and 200-day moving averages cited by Investing.com, while MarketWatch shows the stock close to its recent 52-week high. | Medium-high |
| Risk level | Risk is elevated for a managed-care name because Star Ratings, Medicare Advantage bids, medical utilization, CMS policy, drug costs, and provider economics can reset earnings quickly. | High |
| AI confidence | Descriptive confidence is high because filings and market data are rich. Return confidence is lower because the thesis depends on a policy and margin recovery path. | High data confidence |
| Investment certainty | HUM looks like a recovery execution watch, not a low-uncertainty value setup, at the current price. | Medium-low |
HUM AI stock forecast
HUM AI Stock Forecast Scenarios
The HUM AI stock forecast should be read as scenario math, not a promised price target. Using the July 8, 2026 research cutoff, a $394.62 stock price, FY2026 adjusted EPS guidance of at least $9.00, and a three-year model, the tested range spans a bearish $134 area, a base $296 area, and a bullish $531 area before dividends. The wide range reflects how much future value depends on margin recovery after the 2026 Stars and medical-cost reset.
Base case
$280 to $310
More likely if FY2026 adjusted EPS is near the at least $9.00 guide, earnings compound from a depressed base, and the market applies a 20x multiple to a still uncertain recovery path.
Bearish case
$125 to $145
More likely if medical cost trends stay high, Star Ratings remain a headwind, CMS rules pressure margins, Medicare Advantage membership growth is less profitable, or investors value HUM on depressed earnings.
HUM AI technical analysis
HUM AI Technical Analysis
HUM AI technical analysis is constructive as of the July 8, 2026 data cutoff. The stock was near $394.62, above Investing.com 50-day and 200-day moving averages, with MarketWatch showing a 52-week range of $163.11 to $415.00 and a recent high near $415.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $394.62 | StockAnalysis reported this price with a July 7, 2026 market cap snapshot. |
| Near support | $392 to $395 | The current price and recent day range form the first support area to defend after the sharp rebound. |
| Deeper support | $359 to $360 | Investing.com cited a 200-day moving average near $359.78. Losing this level would weaken the larger trend read. |
| Near resistance | $409 to $415 | MarketWatch reported a recent close near $409.42 and a 52-week range high near $415.00, making this the first upside test. |
| 50-day moving average | $393.44 | Investing.com cited the 50-day moving average as a Buy signal because spot was above the average. |
| 200-day moving average | $359.78 | Investing.com cited the 200-day moving average as a Buy signal, supporting a constructive longer trend until broken. |
| Momentum | Strong buy but RSI neutral | Investing.com described the daily technical read as Strong Buy, while the 14-day RSI around 49 suggested neutral momentum rather than an overbought signal. |
| Volume monitor | About 1.68 million average shares | MarketWatch cited average volume near 1.68 million. Breakouts above $415 should be judged against this reference. |
| Invalidation | Close below $359 | A decisive break below the 200-day moving average would invalidate a trend-following setup and refocus attention on earnings recovery risk. |
HUM AI trading strategy
HUM AI Trading Strategy Framework
The HUM AI trading strategy below is a planning framework for risk control, not personal investment advice. It combines technical confirmation with Medicare Advantage margin evidence because the stock rebound has run ahead of current-year adjusted EPS.
Trend-following setup
Wait for HUM to hold the $392 to $395 area and break above the $409 to $415 resistance zone, then check whether volume is above the 1.68 million share reference and Q2 commentary supports margin recovery.
Treat a failed breakout back below the 50-day moving average as a warning. A close below the 200-day moving average invalidates the trend setup.
Mean-reversion setup
If HUM pulls back toward the 200-day moving average, compare price action with FY2026 EPS guidance, Insurance benefit ratio guidance, MA membership growth quality, and CenterWell patient growth.
Do not average down without a defined exit. A lower guidance reset would matter more than the apparent discount to the recent 52-week high.
Fundamental monitor
Track CMS rate and Stars updates, Medicare Advantage bid commentary, medical cost utilization, FY2026 GAAP EPS of at least $8.36, adjusted EPS of at least $9.00, CenterWell performance, debt, cash, and Q2 results.
Keep position size tied to evidence. Scale in Medicare Advantage does not remove reimbursement, utilization, regulation, or execution risk.
Investment research summary
Four-master Research Compression
Business essence
Humana sells managed healthcare access, risk pooling, care coordination, pharmacy services, primary care, and home health support, primarily for Medicare members. Customers and government programs pay Humana to organize benefits and manage healthcare cost and quality.
Moat
The moat comes from Medicare Advantage scale, provider relationships, Stars operating processes, member data, distribution, pharmacy capabilities, and CenterWell care delivery. The moat narrows when CMS changes rules or medical costs rise faster than pricing.
Munger risk inversion
The thesis fails if membership growth is underpriced, utilization stays elevated, Star Ratings recovery takes longer, CMS reimbursement tightens, CenterWell does not improve total cost of care, or the market refuses to pay a high multiple for uncertain recovery earnings.
Management
Jim Rechtin became President and CEO in July 2024 after joining as President and COO in January 2024. The key management test is whether the team can restore Medicare Advantage margin while improving customer experience and managing leadership changes inside Insurance.
Industry trend
Humana sits in the aging U.S. population and value-based care trend, but the industry is heavily regulated. Long-term demand is favorable, while annual bid cycles, government payment formulas, and utilization shocks can dominate near-term earnings.
Valuation and margin of safety
At $394.62, verified math shows roughly 42.2x TTM EPS and 32.3x FCF per share. Margin of safety depends on earnings recovering materially from FY2026 guidance and on Humana proving that the 2025 to 2026 reset was cyclical rather than structural.
Source-backed data
HUM Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HUM price | $394.62 | StockAnalysis market cap | July 8, 2026 |
| Market cap | $47.38 billion | StockAnalysis market cap | July 8, 2026 |
| Shares outstanding | 120.06 million | MarketWatch quote | July 8, 2026 |
| FY2025 revenue | $129.664 billion | Humana 2025 Form 10-K | July 8, 2026 |
| FY2025 net income attributable to Humana | $1.188 billion | Humana 2025 Form 10-K | July 8, 2026 |
| Insurance segment 2025 premiums and services revenue | $123.842 billion, or 96.3% of consolidated premiums and services revenue | Humana 2025 Form 10-K | July 8, 2026 |
| Individual Medicare Advantage 2025 revenue | $90.403 billion, or 70.3% of consolidated premiums and services revenue | Humana 2025 Form 10-K | July 8, 2026 |
| Cash and equivalents | $4.200 billion at Dec. 31, 2025 | Humana 2025 Form 10-K | July 8, 2026 |
| Total debt | $12.675 billion FY2025 third-party debt reference | StockAnalysis balance sheet | July 8, 2026 |
| FY2026 EPS guidance | GAAP EPS at least $8.36, adjusted EPS at least $9.00 | Humana Q1 2026 earnings release | July 8, 2026 |
| FY2026 individual Medicare Advantage membership outlook | Approximately 25% growth over 2025 | Humana Q1 2026 earnings release | July 8, 2026 |
| 50-day and 200-day moving averages | $393.44 50-day, $359.78 200-day | Investing.com technical analysis | July 8, 2026 |
| 52-week range | $163.11 to $415.00 | MarketWatch quote | July 8, 2026 |
Frequently Asked Questions
Read the HCA AI stock analysisCompare the CI AI stock analysisExplore the AI stock pickerBuild an AI trading strategy
This HUM AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if medical costs, CMS policy, Star Ratings, bid pricing, market multiples, or company execution change.